By AdjAssocProf Craig Haifer

Journal articles

Chetwood JD; Paramsothy S; Haifer C; Leong RW; Kaakoush NO, 2023, 'Key metabolomic alterations are associated with ulcerative colitis disease state and activity: A validation analysis', Gut, http://dx.doi.org/10.1136/gutjnl-2023-330196

Haifer C; Luu LDW; Paramsothy S; Borody TJ; Leong RW; Kaakoush NO, 2023, 'Microbial determinants of effective donors in faecal microbiota transplantation for UC', Gut, 72, pp. 90 - 100, http://dx.doi.org/10.1136/gutjnl-2022-327742

Haifer C; Paramsothy S; Kaakoush NO; Leong RW, 2022, 'Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply', The Lancet Gastroenterology and Hepatology, 7, pp. 286 - 287, http://dx.doi.org/10.1016/S2468-1253(22)00045-0

Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW, 2022, 'Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial', The Lancet Gastroenterology and Hepatology, 7, pp. 141 - 151, http://dx.doi.org/10.1016/S2468-1253(21)00400-3

Haifer C; Saikal A; Paramsothy R; Kaakoush NO; Leong RW; Borody TJ; Kamm MA; Paramsothy S, 2021, 'Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy', Gut, 70, pp. 2210 - 2211, http://dx.doi.org/10.1136/gutjnl-2020-323581

Haifer C; Saikal A; Paramsothy R; Kaakoush NO; Leong RW; Borody TJ; Kamm MA; Paramsothy S, 2021, 'Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy', GUT, 70, pp. 2210 - 2210, http://dx.doi.org/10.1136/gutjnl-2020-323581

Srinivasan A; Haifer C; Thin L, 2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab', Medical Journal of Australia, 215, pp. 435, http://dx.doi.org/10.5694/mja2.51303

Srinivasan A; Haifer C; Thin L, 2021, 'Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD', Alimentary Pharmacology and Therapeutics, 53, pp. 1038 - 1039, http://dx.doi.org/10.1111/apt.16325

Haifer C; Paramsothy S; Borody TJ; Clancy A; Leong RW; Kaakoush NO, 2021, 'Long-term bacterial and fungal dynamics following oral lyophilized fecal microbiota transplantation in clostridioides difficile infection', mSystems, 6, http://dx.doi.org/10.1128/MSYSTEMS.00905-20

Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L, 2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study', Medical Journal of Australia, 214, pp. 128 - 133, http://dx.doi.org/10.5694/mja2.50824

Haifer C; Leong RW; Paramsothy S, 2020, 'The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease', Current Opinion in Pharmacology, 55, pp. 8 - 16, http://dx.doi.org/10.1016/j.coph.2020.08.009

Haifer C; Kelly CR; Paramsothy S; Andresen D; Papanicolas LE; McKew GL; Borody TJ; Kamm M; Costello SP; Andrews JM; Begun J; Chan HT; Connor S; Ghaly S; Johnson PDR; Lemberg DA; Paramsothy R; Redmond A; Sheorey H; Van Der Poorten D; Leong RW, 2020, 'Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice', Gut, 69, pp. 801 - 810, http://dx.doi.org/10.1136/gutjnl-2019-320260

Haifer C; Lawrance IC; Center JR; Clarke MW; Hart PH; Eisman JA; Lucas R; Ghaly S, 2019, 'Vitamin D metabolites are lower with active Crohn’s disease and spontaneously recover with development of remission', Therapeutic Advances in Gastroenterology, 12, http://dx.doi.org/10.1177/1756284819865144

Pudipeddi A; Kariyawasam V; Haifer C; Baraty B; Paramsothy S; Leong RWL, 2019, 'Safety of drugs used for the treatment of Crohn’s disease', Expert Opinion on Drug Safety, 18, pp. 357 - 367, http://dx.doi.org/10.1080/14740338.2019.1612874

Chan W; Shim HH; Ng SC; Liu J; Inglis C; Greveson K; Baraty B; Haifer C; Leong RWL, 2018, 'A global survey of gastroenterologists' travel advice to patients with inflammatory bowel disease on immunosuppressive agents and management of those visiting tuberculosis-endemic areas', Journal of Crohn's and Colitis, 12, pp. 1261 - 1269, http://dx.doi.org/10.1093/ecco-jcc/jjy110

Sood S; Haifer C; Yu L; Pavlovic J; Gow PJ; Jones RM; Visvanathan K; Angus PW; Testro AG, 2018, 'Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation', Transplant Infectious Disease, 20, http://dx.doi.org/10.1111/tid.12934

Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P; Radford-Smith G; Thin L; Baraty B; Haifer C; Yau Y; Leong RWL, 2018, 'Entyvio lengthen dose-interval study: Lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease', European Journal of Gastroenterology and Hepatology, 30, pp. 735 - 740, http://dx.doi.org/10.1097/MEG.0000000000001150

Sood S; Haifer C; Yu L; Pavlovic J; Churilov L; Gow PJ; Jones RM; Angus PW; Visvanathan K; Testro AG, 2017, 'A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation', Liver Transplantation, 23, pp. 487 - 497, http://dx.doi.org/10.1002/lt.24730

Sood S; Haifer C; Yu L; Pavlovic J; Gow PJ; Jones RM; Visvanathan K; Angus PW; Testro AG, 2015, 'Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation', Liver Transplantation, 21, pp. 1478 - 1485, http://dx.doi.org/10.1002/lt.24216

Conference Papers

Tamilarasan AG; Yang X; Zhou L; Haifer C; Katelaris P; Paramsothy S; Leong R, 2022, 'Development and validation of a convolutional neural network model in the detection of Crohn's disease erosions and ulcers by panenteric wireless capsule endoscopy', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 173 - 174, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852585700259&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pudipeddi A; Fung C; Kariyawasam V; Paramsothy R; Ghaly S; Haifer C; An Y; Begun J; Connor S; Chetwood J; Paramsothy S; Leong R, 2022, 'Histological remission using a Nancy index of 0 is associated with longer relapse-free survival than histological activity in patients with ulcerative colitis in clinical and endoscopic remission', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 170 - 170, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852585700253&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haifer C, 2021, 'Catastrophe prevention: Acute severe ulcerative colitis', in Journal of Gastroenterology and Hepatology (Australia), pp. 34, http://dx.doi.org/10.1111/jgh.15459

Haifer C; Srinivasan A; Menon S; An Y; Picardo S; Van Langenberg D; Begun J; Ghaly S; Thin L, 2019, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 155 - 156, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100242&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Suo P; Thin L; Srinivasan A; Winston J; Jeffrey A; Menon S; Ghaly S; Haifer C, 2023, 'Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or safety outcomes after 54 months', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 17, pp. 884 - 884, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000960367601460&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pudipeddi A; Paramsothy S; Kariyawasam V; Paramsothy R; Ghaly S; Haifer C; An YK; Begun J; Connor S; Corte C; Ward M; De Cruz P; Fung C; Redmond D; Leong RW, 2023, 'Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 17, pp. 542 - 542, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000960367601125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Leong R; Haifer C; Kaakoush N; Chetwood J; Pudipeddi A; Paramsothy S, 2022, 'Baseline endoscopic activity and concomitant medications in the prediction of oral fecal microbiota therapeutic efficacy in mild-moderate ulcerative colitis: Lyophilised Oral Faecal Microbiota Transplantation for Ulcerative Colitis (LOTUS) study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 37, pp. 170 - 171, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852585700254&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pudipeddi A; Fung C; Kariyawasam V; Paramsothy R; Ghaly S; Haifer C; An Y; Begun J; Connor S; Chetwood J; Paramsothy S; Leong R, 2022, 'HISTOLOGICAL REMISSION USING A NANCY INDEX OF 0 IS ASSOCIATED WITH LONGER RELAPSE-FREE SURVIVAL THAN HISTOLOGICAL ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL AND ENDOSCOPIC REMISSION', in GUT, BMJ PUBLISHING GROUP, Vol. 71, pp. A149 - A150, http://dx.doi.org/10.1136/gutjnl-2022-IDDF.207

Haifer C; Saikal A; Paramsothy S; Borody TJ; Ghaly S; Kaakoush NO; Leong RW, 2021, 'LYOPHILIZED ORALLY ADMINISTERED FECAL MICROBIOTA TRANSPLANTATION IN THE MANAGEMENT OF ULCERATIVE COLITIS (LOTUS STUDY) - RESULTS FROM THE INDUCTION PHASE OF A RANDOMIZED CONTROLLED TRIAL', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, ELECTR NETWORK, Vol. 160, pp. S135 - S135, presented at Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), ELECTR NETWORK, 21 May 2021 - 23 May 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000649085000323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haifer C; Saikal A; Paramsothy S; Borody TJ; Ghaly S; Kaakoush NO; Leong RW, 2020, 'Lyophilised Oral Faecal Microbiota Transplantation in the Management of Ulcerative Colitis (LOTUS Study): Results from the induction phase of a randomized controlled trial', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 35, pp. 116 - 117, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000589476200169&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Haifer C; Lucas RM; Clarke MW; Lawrance I; Hart PH; Center JR; Eisman JA; Ghaly S, 2018, 'Vitamin D deficiency in Crohn's disease', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 12, pp. S152 - S153, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427318900247&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Preprints

Chen-Liaw A; Aggarwala V; Mogno I; Haifer C; Li Z; Eggers J; Helmus D; Hart A; Wehkamp J; Lamousé-Smith ESN; Kerby RL; Rey FE; Colombel JF; Kamm MA; Borody TJ; Grinspan A; Paramsothy S; Kaakoush NO; Dubinsky MC; Faith JJ, 2022, Gut microbiota bacterial strain richness is species specific and limits therapeutic engraftment, , http://dx.doi.org/10.1101/2022.11.01.514782

Back to profile page